Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7Colorectal Neoplasms 6Stomach Neoplasms 4Biliary Tract Neoplasms 4Esophageal Neoplasms 3Neoplasms 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer (MIBC) 1Metastatic HER2-positive Breast Cancer 1Hemangiosarcoma 1Head and Neck Neoplasms 1HER2-expressing Cancers 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Advanced Malignancies 1

Interventions

Midazolam 2Injections 2zanidatamab 1tislelizumab 1sitravatinib 1repaglinide 1pembrolizumab 1pamiparib 1lenvatinib 1drospirenone 1cemiplimab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Ipilimumab 1HMPL-013 1Gemcitabine 1Ethinyl Estradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignancies × zanidatamab × 1 year × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡